Clonidine Extended-Release Tablets as Add-on Therapy to Psychostimulants in Children and Adolescents With ADHD

Department of Pediatrics, University of California, Irvine, Irvine, California, United States
PEDIATRICS (Impact Factor: 5.3). 06/2011; 127(6):e1406-13. DOI: 10.1542/peds.2010-1260
Source: PubMed

ABSTRACT To assess the efficacy and safety of clonidine hydrochloride extended-release tablets (CLON-XR) combined with stimulants (ie, methylphenidate or amphetamine) for attention-deficit/hyperactivity disorder (ADHD).
In this phase 3, double-blind, placebo-controlled trial, children and adolescents with hyperactive- or combined-subtype ADHD who had an inadequate response to their stable stimulant regimen were randomized to receive CLON-XR or placebo in combination with their baseline stimulant medication. Predefined efficacy measures evaluated change from baseline to week 5. Safety was assessed by spontaneously reported adverse events, vital signs, electrocardiogram recordings, and clinical laboratory values. Improvement from baseline for all efficacy measures was evaluated using analysis of covariance.
Of 198 patients randomized, 102 received CLON-XR plus stimulant and 96 received placebo plus stimulant. At week 5, greater improvement from baseline in ADHD Rating Scale IV (ADHD-RS-IV) total score (95% confidence interval: -7.83 to -1.13; P = .009), ADHD-RS-IV hyperactivity and inattention subscale scores (P = .014 and P = .017, respectively), Conners' Parent Rating Scale scores (P < .062), Clinical Global Impression of Severity (P = .021), Clinical Global Impression of Improvement (P = .006), and Parent Global Assessment (P = .001) was observed in the CLON-XR plus stimulant group versus the placebo plus stimulant group. Adverse events and changes in vital signs in the CLON-XR group were generally mild.
The results of this study suggest that CLON-XR in combination with stimulants is useful in reducing ADHD in children and adolescents with partial response to stimulants.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective In this post hoc analysis, we assessed whether guanfacine extended-release (GXR) adjunctive to a psychostimulant resulted in greater response and remission rates than placebo + psychostimulant in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Method In this 9-week, double-blind, placebo-controlled dose-optimization study, participants (N = 461) aged 6-17 years with suboptimal response to psychostimulants were randomized to GXR on awakening (am) + psychostimulant, GXR at bedtime (pm) + psychostimulant, or placebo + psychostimulant. Results At the final on-treatment assessment, more participants in both GXR plus psychostimulant groups versus the placebo + psychostimulant group achieved response as assessed by 2 criteria: reduction from baseline in ADHD Rating Scale IV (ADHD-RS-IV) total score (1) ≥40% (GXR am + psychostimulant = 69.8%, GXR pm + psychostimulant = 70.3%, versus placebo + psychostimulant = 57.9%; p = .032 and p = .026, respectively), or (2) ≥50% (63.1%, 64.9%, versus 43.4%; p <.001 for both). Results were similar for symptomatic remission (ADHD-RS-IV total score ≤18; 61.1%, 62.2%, versus 46.1%; p = 0.010 and p = 0.005, respectively) and syndromal remission (symptomatic remission plus Clinical Global Impressions of Severity of Illness score ≤2). The most common treatment-emergent adverse events in participants receiving GXR + psychostimulant were headache (21.2%) and somnolence (13.6%). Conclusion GXR + psychostimulant treatment resulted in a greater percentage of participants meeting stringent criteria for response and remission compared with placebo + psychostimulant. The adverse event profile of adjunctive therapy was consistent with known effects of either treatment alone. Clinical trial registration information—Efficacy and Safety of SPD503 in Combination With Psychostimulants;; NCT00734578.
    Journal of the American Academy of Child & Adolescent Psychiatry 10/2014; 53(10). DOI:10.1016/j.jaac.2014.08.001 · 6.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Aufmerksamkeitsdefizit-Hyperaktivitätsstörung, kurz ADHS, ist eine der häufigsten Störungen in der Kinder- und Jugendpsychiatrie mit einer Prävalenz von ca. 5 bis 10 % aller Kinder- und Jugendlichen. Jungen sind dabei etwa 3- bis 4-mal häufiger betroffen als Mädchen. Kernsymptome sind das Aufmerksamkeitsdefizit, die Hyperaktivität und andere Symptome wie gesteigerte Impulsivität und Störungen im Sozialverhalten. Die medikamentöse Therapie von ADHS im Kindes- und Jugendalter ist Baustein einer multimodalen Behandlung mit unterschiedlichen Therapieansätzen. Die α2-adrenergen Agonisten Clonidin und Guanfacin sind in Deutschland bislang nicht zur Therapie der ADHS zugelassen, sie könnten jedoch zukünftig neben den Stimulanzien und anderen Pharmaka als weitere wirksame Therapieoptionen zur Behandlung von ADHS im Kindes- und Jugendalter eine wichtige Rolle spielen.
    Pharmazie in unserer Zeit 11/2011; 40(6). DOI:10.1002/pauz.201100447
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Objective: The purpose of this study was to assess the effect of guanfacine extended release (GXR) adjunctive to a psychostimulant on oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Methods: A multicenter, double-blind, placebo-controlled dose-optimization study of GXR (1-4 mg/d) or placebo administered morning (a.m.) or evening (p.m.) adjunctive to psychostimulant was conducted in subjects ages 6-17 with suboptimal response to psychostimulant alone. Suboptimal response was defined as treatment with a stable dose of psychostimulant for ≥4 weeks with ADHD Rating Scale IV total score ≥24 and Clinical Global Impressions-Severity of Illness score ≥3, as well as investigator opinion. Primary efficacy and safety results have been reported previously. Secondary efficacy measures included the oppositional subscale of the Conners' Parent Rating Scale-Revised: Long Form (CPRS-R:L); these are reported herein. Results: Significant reductions from baseline to the final on-treatment assessment on the oppositional subscale of the CPRS-R:L were seen with GXR plus psychostimulant compared with placebo plus psychostimulant, both in the overall study population (placebo-adjusted least squares [LS] mean change from baseline to the final on-treatment assessment: GXR a.m.+psychostimulant, -2.4, p=0.001; GXR p.m.+psychostimulant, -2.2, p=0.003) as well as in the subgroup of subjects with significant baseline oppositional symptoms (GXR a.m.+psychostimulant, -3.6, p=0.001; GXR p.m.+psychostimulant, -2.7, p=0.013). Treatment-emergent adverse events were reported by 77.3%, 76.3%, and 63.4% of subjects in the GXR a.m., GXR p.m., and placebo groups, respectively, in the overall study population. Conclusions: GXR adjunctive to a psychostimulant significantly reduced oppositional symptoms compared with placebo plus a psychostimulant in subjects with ADHD and a suboptimal response to psychostimulant alone.
    Journal of Child and Adolescent Psychopharmacology 06/2014; 24(5):245-252. DOI:10.1089/cap.2013.0103 · 3.07 Impact Factor

Full-text (2 Sources)

Available from
Jun 4, 2014